This is a 2 hour free software overview of the Neurofield Event Related Potentials (ERP) program created by Dr. Nicholas Dogris.
Learn how this program can be a powerful tool to aid in your assessment, diagnosis, and treatment design for patients. Not only is this a valuable tool to be used for the initial assessment, but it is also excellent to use after administering a series of treatment to truly evaluate progress.
An Introduction to the Event-Related Potential Technique, Second Edition by Steven J. Luck (2014).
“ERP provides a continuous measure of processing, beginning prior to the stimulus and extending past the response […] ERPs give us a measure of the moment-by-moment activity during this period. That is, ERPS show us the “action.” ERPS (and other EEG signals) also give us information about the state of the brain prior to the onset of the stimulus, which has an enormous impact on the way that the stimulus is processed (Worden, Foxe, Wang, & Simpson, 2000; Mathewson, Gratton, Faviani, Beck, & Ro, 2009; Vanrullen, Busch, Drewes, & Dubois, 2011). ERPs also provide information about brain activity that occurs after a response has occurred or after a feedback stimulus has been presented, reflecting executive processes that determine how the brain will operate on subsequent trials (Huloyd & Coles, 2002; Gehring, Liu, Orr, & Carp, 2012)” (p 25).
“The ability to measure processing covertly and continuously over the entire course of a task with millisecond-level temporal resolution makes the ERP technique the best available technique for answering many important questions about the human mind. Much of perception, cognition, and emotion unfolds on a timescale of tens or hundreds of milliseconds, and ERPS are particularly valuable for tracking such rapid sequences of mental operations” (p 27).
“ERPs have the potential to be used as biomarkers in medical applications. That is, ERPs can be used to measure aspects of brain function that are impaired in neurological and psychiatric disease, providing more specific information about an individual patient’s brain function than could be obtained from traditional clinical measures. This information could be used to determine whether a new treatment has an impact on the specific brain system that is being targeted” (p 28-29).